IAPAC guidelines for optimizing the HIV care continuum for adults and adolescents

Journal of the International Association of Providers of AIDS Care

Volumn 14, Issue , 2015, Pages S3-S34

  Bekker, Linda Gail ^b   Montaner, Julio ^b   Ramos, Celso ^b   Sherer, Renslow ^b   Celletti, Francesca ^b   Cutler, Blayne ^b   Dabis, François ^b   Granich, Reuben ^b   Greenberg, Alan ^b   Goldenberg, Shira ^b   Hull, Mark ^b   Kerr, Thomas ^b   Kurth, Ann ^b   Mayer, Kenneth ^b   Metsch, Lisa ^b   Mugo, Nelly R ^b   Munderi, Paula ^b   Nachega, Jean ^b   Nosyk, Bohdan ^b   Saavedra, Jorge ^b   Wolters, Theresa ^b   Young, Benjamin ^b   Zuniga, José M ^a   Agins, Bruce ^b   Amico, K Rivet ^b   Begovac, Josip ^b   Beyrer, Chris ^b   Cahn, Pedro ^b   Cairns, Gus ^b   Cohen, Mardge ^b   Deering, Kathleen ^b   Del Rio, Carlos ^b   Diaz, Ricardo S ^b   Dombrowski, Julia C ^b   Doshi, Rupali ^b   El Sadr, Wafaa ^b   Futterman, Donna ^b   Geretti, Anna Maria ^b   Guaraldi, Giovanni ^b   Halloran, Jim ^b   Gordon, Christopher M ^b   Kahana, Shoshana ^b   Lama, Javier ^b   Lima, Viviane Dias ^b   Linsk, Nathan ^b   Monforte, Antonella D'Arminio ^b   Nelson, Mark ^b   Negussie, Eyerusalem ^b   Phanuphak, Praphan ^b   Scott, James ^b   Shaffer, Douglas ^b   Shannon, Kate ^b   Spaulding, Anne ^b   Valerio, Carlos ^b   Wu, Zunyou ^b   Zakowicz, Anna ^b   Zorrilla, Carmen ^b   more..

^a INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE   (United States)

^b NONE

Author keywords

antiretroviral therapy; continuum of care; HIV; testing; viral suppression

Indexed keywords

INTEGRASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; ADULT; ADVERSE OUTCOME; AGE DISTRIBUTION; ANTIVIRAL RESISTANCE; ANXIETY DISORDER; CASE MANAGEMENT; CASE MANAGER; CD4 LYMPHOCYTE COUNT; CINAHL; CIRCUMCISION; CLINICAL PHARMACY; COMMUNITY CARE; CONDOM USE; CROSS-SECTIONAL STUDY; DEPRESSION; DISEASE SURVEILLANCE; DRUG EFFICACY; EARLY INTERVENTION; EDUCATION PROGRAM; ELECTRONIC MEDICAL RECORD; EMBASE; ENVIRONMENTAL HEALTH; EPIDEMIOLOGICAL DATA; ETHNIC GROUP; EVIDENCE BASED PRACTICE; FOLLOW UP; HARM REDUCTION; HEALTH CARE; HEALTH CARE DELIVERY; HEALTH CARE FACILITY; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; HEALTH EDUCATION; HEALTH PERSONNEL ATTITUDE; HEALTH PROGRAM; HEALTH STATUS; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION PREVENTION; INFECTION RISK; LAW; MANAGED CARE; MEDICATION COMPLIANCE; MEMORY DISORDER; MEN WHO HAVE SEX WITH MEN; META ANALYSIS (TOPIC); OBSERVATIONAL STUDY; OCCUPATIONAL EXPOSURE; PATIENT CARE; PATIENT EDUCATION; PATIENT MONITORING; PATIENT REFERRAL; POST EXPOSURE PROPHYLAXIS; POSTTRAUMATIC STRESS DISORDER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRISONER; PROSTITUTION; PSYCINFO; PUBLIC HEALTH SERVICE; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESIDENTIAL CARE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCREENING TEST; SELF CARE; SELF EVALUATION; SEX DIFFERENCE; SEXUAL BEHAVIOR; SEXUAL ORIENTATION; SOCIAL BEHAVIOR; SOCIAL DISCRIMINATION; SOCIAL STIGMA; SYSTEMATIC REVIEW; TRAFFIC AND TRANSPORT; TRANSGENDER; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; VIRAL LOAD TESTING; WORKPLACE; ADOLESCENT HEALTH; HIV INFECTIONS; IMMUNOLOGY;

ADOLESCENT; ADOLESCENT HEALTH; ADULT; ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84948408887     PISSN: 23259574     EISSN: 23259582     Source Type: Journal    
DOI: 10.1177/2325957415613442     Document Type: Review

References (314)

1. Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013; 8 (12): e81355.
2. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011; 365 (6): 493-505.
3. Wood E, Kerr T, Marshall BDL, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ. 2009; 338: b1649.
4. De Cock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA. 2000; 283 (9): 1175-1182.
5. Montaner JS, Hogg R, Wood E, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet. 2006; 368 (9534): 531-536.
6. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG,. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009; 373 (9657): 48-57.
7. Montaner JS, Lima VD, Harrigan PR, et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the "HIV Treatment as Prevention" experience in a Canadian setting. PLoS One. 2014; 9 (2): e87872.
8. Joint United Nations Programme on HIV/AIDS. 90-90-90 An ambitious treatment target to help end the AIDS epidemic. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS; 2014. Web site. http://www.unaids.org/en/resources/documents/2014/90-90-90. Accessed October 15, 2015.
9. Joint United Nations Programme on HIV/AIDS. 15 by 15: a global target achieved. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS; 2015. Web site. http://www.unaids.org/sites/default/files/media-asset/UNAIDS-15by15-en.pdf. Accessed October 15, 2015.
10. Joint United Nations Programme on HIV/AIDS. World AIDS Day 2014 Report-Fact sheet. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS; 2014. Web site. http://www.unaids.org/en/resources/campaigns/World-AIDS-Day-Report-2014/factsheet. Accessed October 15, 2015.
11. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ,. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011; 52 (6): 793-800.
12. Granich R, Gupta S, Montaner J, Williams B, Zuniga JM,. Pattern, determinants and impact of HIV spending on care and treatment in 39 high burden countries. J Int Assoc Provid AIDS Care. 2015. Pending publication.
13. Pineirua A, Sierra-Madero J, Cahn P, Guevara Palmero R, Martinez E, Young B,. The HIV care cascade in Latin America: challenges and opportunities. Lancet. 2015; 15 (7): 833-839.
14. Centers for Disease Control and Prevention. Understanding the HIV Care Continuum. Centers for Disease Control and Prevention.; 2014. Web site. http://www.cdc.gov/hiv/pdf/dhap-continuum.pdf. Accessed October 15, 2015.
15. Govindasamy D, Meghij J, Negussi EK, Baggaley RC, Ford N, Kranzer K,. Interventions to improve or facilitate linkage to or retention in pre-ART (HIV) care and initiation of ART in low- and middle-income settings-a systematic review. J Int AIDS Soc. 2014; 17 (1): 19032.
16. Beyrer C, Sullivan P, Sanchez J, et al. The increase in global HIV epidemics in MSM. AIDS. 2013; 27 (17): 2665-2678.
17. Shannon K, Strathdee SA, Goldenberg SM, et al. Global epidemiology of HIV among female sex workers: influence of structural determinants. Lancet. 2015; 385 (9962): 55-71.
18. Baral SD, Friedman MR, Geibel S, et al. Male sex workers: practices, contexts, and vulnerabilities for HIV acquisition and transmission. Lancet. 2015; 385 (9964): 260-273.
19. Poteat T, Wirtz AL, Radix A, et al. HIV risk and preventive interventions in transgender women sex workers. Lancet. 2015; 385 (9964): 274-286.
20. Arreola S, Santos GM, Beck J, et al. Sexual stigma, criminalization, investment, and access to HIV services among men who have sex with men worldwide. AIDS Behav. 2015; 19 (2): 227-234.
21. Lehman JS, Carr MH, Nichol AJ, et al. Prevalence and public health implications of state laws that criminalize potential HIV exposure in the United States. AIDS Behav. 2014; 18 (6): 997-1006.
22. Canadian HIV/AIDS Legal Network. A Human Rights Analysis of the N'djamena model legislation on AIDS and HIV specific legislation in Benin, Guinea, Guinea Bissau, Mali, Niger, Sierra Leone and Togo. Toronto: Canadian HIV/AIDS Legal Network; 2007. Web site. http://www.aidslaw.ca/site/wpcontent/uploads/2013/03/LN-HumanRtLegislnRvw-en.pdf. Accessed October 15, 2015.
23. World Health Organization. Report of the WHO European Region Technical Consultation, in collaboration with the European AIDS Treatment Group (EATG) and AIDS Action Europe (AAE), on the Criminalization of HIV and Other Sexually Transmitted Infections. Copenhagen: World Health Organization; 2006. Web site. http://www.hivlawandpolicy.org/sites/www.hivlawandpolicy.org/files/WHO%20consultation%20on%20crim%20laws.pdf. Accessed October 15, 2015.
24. Lazzarini Z, Bray S, Burris S,. Evaluating the impact of criminal laws on HIV risk behavior. J Law Med Ethics. 2002; 30 (2): 239-253.
25. Burris S, Beletsky L, Burleson J, Case P, Lazzarini Z,. Do criminal laws effect HIV risk behavior? An empirical trial. Ariz St L J. 2007; 39: 467-517.
26. Galletly CL, Glasman LR, Pinkerton SD, Difranceisco W,. New Jersey's HIV exposure law and the HIV-related attitudes, beliefs, and sexual and seropositive status disclosure behaviors of persons living with HIV. Am J Public Health. 2012; 102 (11): 2135-2140.
27. Galletly CL, Pinkerton SD,. Preventing HIV transmission via HIV exposure laws: applying logic and mathematical modeling to compare statutory approaches to penalizing undisclosed exposure to HIV. J Law Med Ethics. 2008; 36 (3): 577-584.
28. Horvath KJ, Weinmeyer R, Rosser S,. Should it be illegal for HIV-positive persons to have unprotected sex without disclosure? An examination of attitudes among US men who have sex with men and the impact of state law. AIDS Care. 2010; 22 (10): 1221-1228.
29. National Institute of Allergy and Infectious Diseases. Scientific Evidence on Condom Effectiveness for Sexually Transmitted Disease (STD) Prevention. Bethesda, DC: National Institute of Allergy and Infectious Diseases; 2001. Web site. http://www.niaid.nih.gov/about/organization/dmid/documents/condomreport.pdf. Accessed October 15, 2015.
30. Holmes KK, Levine R, Weaver M,. Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ. 2004; 82 (6): 454-461.
31. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011; 365 (6): 493-505.
32. McCormack S, Dunn D,. Pragmatic Open-Label Randomised Trial of Preexposure Prophylaxis: The PROUD Study. Presented at: Conference on Retroviruses and Opportunistic Infections; February 23-26, 2015; Seattle, WA.
33. Bunnell R, Ekwaru JP, Solberg P, et al. Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS. 2006; 20 (1): 85-92.
34. Marks G, Crepaz N, Senterfitt JW, Janssen RS,. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr. 2005; 39 (4): 446-453.
35. Grubb IR, Beckham SW, Kazatchkine M, et al. Maximizing the benefits of antiretroviral therapy for key affected populations. J Int AIDS Soc. 2014; 17 (1): 19320.
36. Jurgens R, Cohen J, Cameron E, et al. Ten reasons to oppose the criminalization of HIV exposure or transmission. Reprod Health Matters. 2009; 17 (34): 163-172.
37. Cameron E,. Criminalization of HIV transmission: poor public health policy. HIV AIDS Policy Law Rev. 2009; 14 (2): 63-75.
38. Lazarus JV, Curth N, Weait M, Matic S,. HIV-related restrictions on entry, residence and stay in the WHO European Region: a survey. J Int AIDS Soc. 2010; 13: 2.
39. Amon JJ, Todrys KW,. Fear of Foreigners: HIV-related restrictions on entry, stay, and residence. J Int AIDS Soc. 2008; 11: 8.
40. Mills EJ, Ford N, Singh S, Eyawo O,. Providing antiretroviral care in conflict settings. Curr HIV/AIDS Rep. 2009; 6 (4): 201-209.
41. Zelaya CE, Sivaram S, Johnson SC, Srikrishnan AK, Suniti S, Celentano DD,. Measurement of self, experienced, and perceived HIV/AIDS stigma using parallel scales in Chennai, India. AIDS Care. 2012; 24 (7): 846-855.
42. Makoae LN, Portillo CJ, Uys LR, et al. The impact of taking or not taking ARVs on HIV stigma as reported by persons living with HIV infection in five African countries. AIDS Care. 2009; 21 (11): 1357-1362.
43. Trost G, Vierneisel C, Gornski H, Petrov I,. The PLHIV Stigma Index in Germany: Results of the Community Initiative on HIV-Related Stigmatization. Presented at: XIX International AIDS Conference; July 22-27, 2012; Washington, DC.
44. Lorente N, Preau M, Vernay-Vaisse C, et al. Expanding access to non-medicalized community-based rapid testing to men who have sex with men: an urgent HIV prevention intervention (The ANRS-DRAG Study). PLoS One. 2013; 8 (4): e61225.
45. Stangl AL, Lloyd JK, Brady LM, Holland CE, Baral S,. A systematic review of interventions to reduce HIV-related stigma and discrimination from 2002 to 2013: how far have we come? J Int AIDS Soc. 2013; 16 (3 suppl 2): 18734.
46. World Health Organization. HIV testing, treatment and prevention: generic tools for operational research. Geneva, Switzerland: World Health Organization; 2009. Web site. http://www.who.int/hiv/pub/operational/or-generic-tools.pdf. Accessed October 15, 2015.
47. Pulerwitz J, Michaelis A, Weiss E, Brown L, Mahendra V,. Reducing HIV-related stigma: lessons learned from Horizons research and programs. Public Health Rep. 2010; 125 (2): 272-281.
48. Human Sciences Research Council. The People Living With HIV Stigma Index: South Africa 2014. South Africa: Human Sciences Research Council; 2015. Web site. http://www.stigmaindex.org/sites/default/files/reports/Summary-Booklet-on-Stigma-Index-Survey%20South%20Africa.pdf. Accessed October 15, 2015.
49. Sin NL, DiMatteo MR,. Depression treatment enhances adherence to antiretroviral therapy: a meta-analysis. Ann Behav Med. 2014; 47 (3): 259-269.
50. Pyne JM, Fortney JC, Curran GM, et al. Effectiveness of collaborative care for depression in human immunodeficiency virus clinics. Arch Intern Med. 2011; 171 (1): 23-31.
51. Safren SA, O'Cleirigh C, Tan JY, et al. A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health Psychol. 2009; 28 (1): 1-10.
52. Brandt R,. The mental health of people living with HIV/AIDS in Africa: a systematic review. Afr J AIDS Res. 2009; 8 (2): 123-133.
53. Rabkin JG,. HIV and depression: 2008 review and update. Curr HIV/AIDS Rep. 2008; 5 (4): 163-171.
54. Bouhnik AD, Preau M, Vincent E, et al. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy. Antivir Ther. 2005; 10 (1): 53-61.
55. Carrieri MP, Chesney MA, Spire B, et al. Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users. Int J Behav Med. 2003; 10 (1): 1-14.
56. Swendeman D, Rotheram-Borus MJ,. Innovation in sexually transmitted disease and HIV prevention: internet and mobile phone delivery vehicles for global diffusion. Curr Opin Psychiatry. 2010; 23 (2): 139-144.
57. Druss BG, Zhao L, von Esenwein SA, et al. The Health and Recovery Peer (HARP) Program: a peer-led intervention to improve medical self-management for persons with serious mental illness. Schizophr Res. 2010; 118 (1-3): 264-270.
58. Millard T, Elliott J, Girdler S,. Self-management education programs for people living with HIV/AIDS: a systematic review. AIDS Patient Care STDS. 2013; 27 (2): 103-113.
59. Johnson MO, Neilands TB, Dilworth SE, Morin SF, Remien RH, Chesney MA,. The role of self-efficacy in HIV treatment adherence: validation of the HIV Treatment Adherence Self-Efficacy Scale (HIV-ASES). J Behav Med. 2007; 30 (5): 359-370.
60. Johnson MO, Dilworth SE, Taylor JM, Neilands TB,. Improving coping skills for self-management of treatment side effects can reduce antiretroviral medication nonadherence among people living with HIV. Ann Behav Med. 2011; 41 (1): 83-91.
61. Wolf MS, Davis TC, Osborn CY, Skripkauskas S, Bennett CL, Makoul G,. Literacy, self-efficacy, and HIV medication adherence. Patient Educ Couns. 2007; 65 (2): 253-260.
62. Battersby M, Von Korff M, Schaefer J, et al. Twelve evidence-based principles for implementing self-management support in primary care. Jt Comm J Qual Patient Saf. 2010; 36 (12): 561-570.
63. Ramanathan N, Swendeman D, Comulada WS, Estrin D, Rotheram-Borus MJ,. Identifying preferences for mobile health applications for self-monitoring and self-management: focus group findings from HIV-positive persons and young mothers. Int J Med Inform. 2013; 82 (4): e38-e46.
64. Tufts KA, Johnson KF, Shepherd JG, et al. Novel interventions for HIV self-management in African American women: a systematic review of mHealth interventions. J Assoc Nurses AIDS Care. 2015; 26 (2): 139-150.
65. Millard T, Elliott J, Slavin S, McDonald K, Rowell S, Girdler S,. The positive outlook study- a randomised controlled trial evaluating the effectiveness of an online self-management program targeting psychosocial issues for men living with HIV: a study protocol. BMC Public Health. 2014; 14: 106.
66. Millard T, McDonald K, Elliott J, Slavin S, Rowell S, Girdler S,. Informing the development of an online self-management program for men living with HIV: a needs assessment. BMC Public Health. 2014; 14: 1209.
67. World Health Organization. Task shifting: global recommendations and guidelines. Geneva, Switzerland: World Health Organization; 2008. Web site. http://www.who.int/workforcealliance/knowledge/resources/taskshifting-guidelines/en/. Accessed October 15, 2015.
68. Chiambe G, Kulzer J, Nyabiage L, Bukuzi E, Penner J, Cohen C,. Maximizing Human Resources by Involving Lay Health Workers in HIV Service Delivery in Kenya. Presented at: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 19-22, 2009. Cape Town, South Africa.
69. Ledikwe JH, Kejelepula M, Maupo K, et al. Evaluation of a well-established task-shifting initiative: the lay counselor cadre in Botswana. PLoS One. 2013; 8 (4): e61601.
70. Morris MB, Chapula BT, Chi BH, et al. Use of task-shifting to rapidly scale-up HIV treatment services: experiences from Lusaka, Zambia. BMC Health Serv Res. 2009; 9: 5.
71. Grimwood A, Fatti G, Mothibi E, Malahlela M, Shea J, Eley B,. Community adherence support improves programme retention in children on antiretroviral treatment: a multicentre cohort study in South Africa. J Int AIDS Soc. 2012; 15 (2): 17381.
72. Kenya S, Chida N, Symes S, Shor-Posner G,. Can community health workers improve adherence to highly active antiretroviral therapy in the USA? A review of the literature. HIV Med. 2011; 12 (9): 525-534.
73. Tobin KE, Tang AM, Gilbert SH, Latkin CA,. Correlates of HIV antibody testing among a sample of injection drug users: the role of social and contextual factors. AIDS Behav. 2004; 8 (3): 303-310.
74. Wilton L, Herbst JH, Coury-Doniger P, et al. Efficacy of an HIV/STI prevention intervention for black men who have sex with men: findings from the Many Men, Many Voices (3MV) project. AIDS Behav. 2009; 13 (3): 532-544.
75. Meulbroek M, Ditzel E, Saz J, et al. BCN Checkpoint, a community-based centre for men who have sex with men in Barcelona, Catalonia, Spain, shows high efficiency in HIV detection and linkage to care. HIV Med. 2013; 14 (suppl 3): 25-28.
76. Chamie G, Kwarisiima D, Clark TD, et al. Uptake of community-based HIV testing during a multi-disease health campaign in rural Uganda. PLoS One. 2014; 9 (1): e84317.
77. Champenois K, Le Gall JM, Jacquemin C, et al. ANRS-COM'TEST: description of a community-based HIV testing intervention in non-medical settings for men who have sex with men. BMJ Open. 2012; 2 (2): e000693.
78. Muhamadi L, Tumwesigye NM, Kadobera D, et al. A single-blind randomized controlled trial to evaluate the effect of extended counseling on uptake of pre-antiretroviral care in Eastern Uganda. Trials. 2011; 12: 184.
79. Chang LW, Kagaayi J, Nakigozi G, et al. Effect of peer health workers on AIDS care in Rakai, Uganda: a cluster-randomized trial. PLoS One. 2010; 5 (6): e10923.
80. Kabore I, Bloem J, Etheredge G, et al. The effect of community-based support services on clinical efficacy and health-related quality of life in HIV/AIDS patients in resource-limited settings in sub-Saharan Africa. AIDS Patient Care STDs. 2010; 24 (9): 581-594.
81. Kenya S, Chida N, Symes S, Shor-Posner G,. Can community health workers improve adherence to highly active antiretroviral therapy in the USA? A review of the literature. HIV Med. 2011; 12 (9): 525-534.
82. Wang H, Zhou J, Huang L, Li X, Fennie KP, Williams AB,. Effects of nurse-delivered home visits combined with telephone calls on medication adherence and quality of life in HIV-infected heroin users in Hunan of China. J Clin Nurs. 2010; 19 (3-4): 380-388.
83. Ko NY, Lai YY, Liu HY, et al. Impact of the nurse-led case management program with retention in care on mortality among people with HIV-1 infection: a prospective cohort study. Int J Nurs Stud. 2012; 49 (6): 656-663.
84. Grimsrud A, Kaplan R, Bekker LG, Myer L,. Outcomes of a nurse-managed service for stable HIV-positive patients in a large South African public sector antiretroviral therapy programme. Trop Med Int Health. 2014; 19 (9): 1029-1039.
85. Decroo T, Mondlane V, Dos Santos N, et al. Community ART Groups Support ART Access and Retention among HIV-Positive Dependent Children in rural Tete, Mozambique. Presented at: 19th International AIDS Conference; July 22-27, 2012; Washington, DC.
86. Naar-King S, Outlaw A, Green-Jones M, Wright K, Parsons JT,. Motivational interviewing by peer outreach workers: a pilot randomized clinical trial to retain adolescents and young adults in HIV care. AIDS Care. 2009; 21 (7): 868-873.
87. Wouters E, Van Damme W, van Rensburg D, Masquillier C, Meulemans H,. Impact of community-based support services on antiretroviral treatment programme delivery and outcomes in resource-limited countries: a synthetic review. BMC Health Serv Res. 2012; 12: 194.
88. Wamboga Magawa J, Mpiima D,. Community ART Delivery Model for High Retention of Patients on Antiretroviral Therapy: The AIDS Support Organisation (TASO) Operational Research Findings East and Central Uganda, Resource-Limited Setting. Presented at: 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; June 30-July 3, 2013; Kuala Lumpur, Malaysia.
89. Munoz M, Bayona J, Sanchez E, et al. Matching social support to individual needs: a community-based intervention to improve HIV treatment adherence in a resource-poor setting. AIDS Behav. 2011; 15 (7): 1454-1464.
90. Wouters E, Van Loon F, Van Rensburg D, Meulemans H,. State of the ART: clinical efficacy and improved quality of life in the public antiretroviral therapy program, Free State province, South Africa. AIDS Care. 2009; 21 (11): 1401-1411.
91. Chang L, Nakigozi G, Mulamba J, et al. The PeerCARE Study, a Randomized, Controlled Trial of the Impact of Peers on Linkage to Care, Preventive Care and Sexual Behaviours among PLHIV not on Antiretroviral Therapy: Baseline Findings. Presented at: 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Jun 30-Jul 3, 2013. Kuala Lumpur, Malaysia.
92. Gusdal AK, Obua C, Andualem T, Wahlstrom R, Chalker J, Fochsen G,. Peer counselors' role in supporting patients' adherence to ART in Ethiopia and Uganda. AIDS Care. 2011; 23 (6): 657-662.
93. Arem H, Nakyanjo N, Kagaayi J, et al. Peer health workers and AIDS care in Rakai, Uganda: a mixed methods operations research evaluation of a cluster-randomized trial. AIDS Patient Care STDs. 2011; 25 (12): 719-724.
94. Tenthani L, Cataldo F, Chan AK, Bedell R, Martiniuk AL, van Lettow M,. Involving expert patients in antiretroviral treatment provision in a tertiary referral hospital HIV clinic in Malawi. BMC Health Serv Res. 2012; 12: 140.
95. Danel C, Gabillard D, Le Carrou J, et al. Early ART and IPT in HIV-Infected African Adults With High CD4 Count (TEMPRANO Trial). Presented at: Conference on Retroviruses and Opportunistic Infections; February 23-26, 2015; Seattle, WA.
96. Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015; 373 (9): 795-807.
97. Branson B, Handsfield H, Lampe M, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. Atlanta, GA: CDC; 2006. Web site. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5514a1.htm. Accessed October 15, 2015.
98. Craw J, Gardner L, Rossman A, et al. Structural factors and best practices in implementing a linkage to HIV care program using the ARTAS model. BMC Health Serv Res. 2010; 10: 246.
99. Elul B, Lahuerta M, Abacassamo F, et al. A combination strategy for enhancing linkage to and retention in HIV care among adults newly diagnosed with HIV in Mozambique: study protocol for a site-randomized implementation science study. BMC Infect Dis. 2014; 14: 549.
100. Bauman LJ, Braunstein S, Calderon Y, et al. Barriers and facilitators of linkage to HIV primary care in New York City. J Acquir Immune Defic Syndr. 2013; 64 (suppl 1): S20-S26.
101. Koester KA, Morewitz M, Pearson C, et al. Patient navigation facilitates medical and social services engagement among HIV-infected individuals leaving jail and returning to the community. AIDS Patient Care and STDs. 2014; 28 (2): 82-90.
102. Rosen S, Fox MP,. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med. 2011; 8 (7): e1001056.
103. Govindasamy D, Ford N, Kranzer K,. Risk factors, barriers and facilitators for linkage to antiretroviral therapy care: a systematic review. AIDS. 2012; 26 (16): 2059-2067.
104. World Health Organization. Consolidated Guidelines on HIV Testing Services. 5Cs: Consent, Confidentiality, Counselling, Correct Results and Connection. Geneva, Switzerland: World Health Organization; 2015. Web site. http://apps.who.int/iris/bitstream/10665/179870/1/9789241508926-eng.pdf?ua=1&ua=1. Accessed October 15, 2015.
105. Duffus WA, Davis HT, Byrd MD, Heidari K, Stephens TG, Gibson JJ,. HIV testing in women: missed opportunities. J Womens Health. 2012; 21 (2): 170-178.
106. Centers for Disease Control and Prevention (CDC). Missed opportunities for earlier diagnosis of HIV infection-South Carolina, 1997-2005. MMWR Morb Mortal Wkly Rep. 2006; 55 (47): 1269-1272.
107. Leon N, Naidoo P, Mathews C, Lewin S, Lombard C,. The impact of provider-initiated (opt-out) HIV testing and counseling of patients with sexually transmitted infection in Cape Town, South Africa: a controlled trial. Implement Sci. 2010; 5: 8.
108. Leber W, McMullen H, Anderson J, et al. Promotion of rapid testing for HIV in primary care (RHIVA2): a cluster-randomised controlled trial. Lancet. 2015; 2 (6): e229-e235.
109. Sweat M, Morin S, Celentano D, et al. Community-based intervention to increase HIV testing and case detection in people aged 16-32 years in Tanzania, Zimbabwe, and Thailand (NIMH Project Accept, HPTN 043): a randomised study. Lancet Infect Dis. 2011; 11 (7): 525-532.
110. Suthar AB, Lawn SD, del Amo J, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med. 2012; 9 (7): e1001270.
111. Simaputtanasan A, Phanjaroen K, Pankam T, et al. High Uptake of Mobile HIV Testing in Bangkok Metropolitan Area, Thailand. Presented at: 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; June 30-July 3, 2013; Kuala Lumpur, Malaysia.
112. Kawichai S, Celentano DD, Chariyalertsak S, et al. Community-based voluntary counseling and testing services in rural communities of Chiang Mai Province, Northern Thailand. AIDS Behav. 2007; 11 (5): 770-777.
113. Lahuerta M, Sabido M, Giardina F, et al. Comparison of users of an HIV/syphilis screening community-based mobile van and traditional voluntary counselling and testing sites in Guatemala. Sex Transm Infect. 2011; 87 (2): 136-140.
114. Nhurod P, Bollen LJ, Smutraprapoot P, et al. Access to HIV testing for sex workers in Bangkok, Thailand: a high prevalence of HIV among street-based sex workers. Southeast Asian J Trop Med Public Health. 2010; 41 (1): 153-162.
115. Sekandi JN, Sempeera H, List J, et al. High acceptance of home-based HIV counseling and testing in an urban community setting in Uganda. BMC Public Health. 2011; 11: 730.
116. Helleringer S, Kohler HP, Frimpong JA, Mkandawire J,. Increasing uptake of HIV testing and counseling among the poorest in sub-Saharan countries through home-based service provision. J Acquir Immune Defic Syndr. 2009; 51 (2): 185-193.
117. Medley A, Ackers M, Amolloh M, et al. Early uptake of HIV clinical care after testing HIV-positive during home-based testing and counseling in western Kenya. AIDS Behav. 2013; 17 (1): 224-234.
118. Suthar AB, Ford N, Bachanas PJ, et al. Towards universal voluntary HIV testing and counselling: a systematic review and meta-analysis of community-based approaches. PLoS Med. 2013; 10 (8): e1001496.
119. Ransome Y, Terzian A, Addison D, Braunstein S, Myers J, Nash D,. Expanded HIV Testing Coverage is Ecologically Associated with Decreases in the Number of Late HIV Diagnoses, New York City, 2001-2010. Presented at: 8th International Conference on HIV Treatment and Prevention Adherence; June 2-4, 2013; Miami, FL.
120. Castel AD, Magnus M, Peterson J, et al. Implementing a novel citywide rapid HIV testing campaign in Washington, D.C.: findings and lessons learned. Public Health Rep. 2012; 127 (4): 422-431.
121. Chamie G, Kwarisiima D, Clark TD, et al. Leveraging rapid community-based HIV testing campaigns for non-communicable diseases in rural Uganda. PLoS One. 2012; 7 (8): e43400.
122. Lugada E, Millar D, Haskew J, et al. Rapid implementation of an integrated large-scale HIV counseling and testing, malaria, and diarrhea prevention campaign in rural Kenya. PLoS One. 2010; 5 (8): e12435.
123. Kahn JG, Harris B, Mermin JH, et al. Cost of community integrated prevention campaign for malaria, HIV, and diarrhea in rural Kenya. BMC Health Serv Res. 2011; 11: 346.
124. Kahn JG, Muraguri N, Harris B, et al. Integrated HIV testing, malaria, and diarrhea prevention campaign in Kenya: modeled health impact and cost-effectiveness. PLoS One. 2012; 7 (2): e31316.
125. Hatcher AM, Turan JM, Leslie HH, et al. Predictors of linkage to care following community-based HIV counseling and testing in rural Kenya. AIDS Behav. 2012; 16 (5): 1295-1307.
126. Adjei AA, Armah HB, Gbagbo F, et al. Correlates of HIV, HBV, HCV and syphilis infections among prison inmates and officers in Ghana: a national multicenter study. BMC Infect Dis. 2008; 8: 33.
127. Arora U, Chopra S,. Seropositivity of HIV infection among armed forces attending integrated testing and counseling centre in a tertiary care hospital. Indian J Public Health. 2010; 54 (1): 45.
128. Azuonwu O, Erhabor O, Obire O,. HIV among military personnel in the Niger Delta of Nigeria. J Community Health. 2012; 37 (1): 25-31.
129. Houdmont J, Munir F, Grey M,. Acceptance of repeat worksite HIV voluntary counselling and testing in a rural South African factory. AIDS Care. 2013; 25 (9): 1199-1202.
130. Riviello ED, Sterling TR, Shepherd B, Fantan T, Makhema J,. HIV in the workplace in Botswana: incidence, prevalence, and disease severity. AIDS Res Hum Retroviruses. 2007; 23 (12): 1453-1460.
131. Kalibala S, Tun W, Cherutich P, Nganga A, Oweya E, Oluoch P,. Factors associated with acceptability of HIV self-testing among health care workers in Kenya. AIDS Behav. 2014; 18 (suppl 4): S405-S414.
132. Choko AT, Desmond N, Webb EL, et al. The uptake and accuracy of oral kits for HIV self-testing in high HIV prevalence setting: a cross-sectional feasibility study in Blantyre, Malawi. PLoS Med. 2011; 8 (10): e1001102.
133. Carballo-Dieguez A, Frasca T, Balan I, Ibitoye M, Dolezal C,. Use of a rapid HIV home test prevents HIV exposure in a high risk sample of men who have sex with men. AIDS Behav. 2012; 16 (7): 1753-1760.
134. Pant Pai N, Bhargava M, Joseph L, et al. Will an unsupervised self-testing strategy be feasible to operationalize in Canada? Results from a pilot study in students of a large Canadian university. AIDS Res Treat. 2014; 2014: 747619.
135. Choko AT, MacPherson P, Webb EL, et al. One Year Outcomes Following Community-Based HIV Self-Testing: A Prospective Study in Malawi. Presented at: Conference on Retroviruses and Opportunistic Infections. March 3-6, 2014; Boston, MA.
136. Cambiano V, Ford D, Mabugu T, et al. Assessment of the potential impact and cost-effectiveness of self-testing for HIV in low-income countries. J Infect Dis. 2015; 212 (4): 570-577.
137. Oster AM, Wejnert C, Mena LA, Elmore K, Fisher H, Heffelfinger JD,. Network analysis among HIV-infected young black men who have sex with men demonstrates high connectedness around few venues. Sex Transm Dis. 2013; 40 (3): 206-212.
138. Hogben M, McNally T, McPheeters M, Hutchinson AB,. The effectiveness of HIV partner counseling and referral services in increasing identification of HIV-positive individuals a systematic review. Am J Prev Med. 2007; 33 (2 suppl): S89-S100.
139. Fuqua V, Chen YH, Packer T, et al. Using social networks to reach black MSM for HIV testing and linkage to care. AIDS Behav. 2012; 16 (2): 256-265.
140. Schneider JA, Saluja GS, Oruganti G, et al. HIV infection dynamics in rural Andhra Pradesh south India: a sexual-network analysis exploratory study. AIDS Care. 2007; 19 (9): 1171-1176.
141. Kimbrough LW, Fisher HE, Jones KT, Johnson W, Thadiparthi S, Dooley S,. Accessing social networks with high rates of undiagnosed HIV infection: the social networks demonstration project. Am J Public Health. 2009; 99 (6): 1093-1099.
142. Brown LB, Miller WC, Kamanga G, et al. HIV partner notification is effective and feasible in sub-Saharan Africa: opportunities for HIV treatment and prevention. J Acquir Immune Defic Syndr. 2011; 56 (5): 437-442.
143. Creek T, Ntumy R, Mazhani L, et al. Factors associated with low early uptake of a national program to prevent mother to child transmission of HIV (PMTCT): results of a survey of mothers and providers, Botswana, 2003. AIDS Behav. 2009; 13 (2): 356-364.
144. Panditrao M, Darak S, Kulkarni V, Kulkarni S, Parchure R,. Socio-demographic factors associated with loss to follow-up of HIV-infected women attending a private sector PMTCT program in Maharashtra, India. AIDS Care. 2011; 23 (5): 593-600.
145. Torian LV, Wiewel EW, Liu KL, Sackoff JE, Frieden TR,. Risk factors for delayed initiation of medical care after diagnosis of human immunodeficiency virus. Arch Intern Med. 2008; 168 (11): 1181-1187.
146. Wanyenze RK, Hahn JA, Liechty CA, et al. Linkage to HIV care and survival following inpatient HIV counseling and testing. AIDS Behav. 2011; 15 (4): 751-760.
147. Christopoulos KA, Kaplan B, Dowdy D, et al. Testing and linkage to care outcomes for a clinician-initiated rapid HIV testing program in an urban emergency department. AIDS Patient Care STDs. 2011; 25 (7): 439-444.
148. MacPherson P, Lalloo DG, Choko AT, et al. Suboptimal patterns of provider initiated HIV testing and counselling, antiretroviral therapy eligibility assessment and referral in primary health clinic attendees in Blantyre, Malawi. Trop Med Int Health. 2012; 17 (4): 507-517.
149. Baeten J, Heffron R, Kidoguchi L, et al. Near Elimination of HIV Transmission in a Demonstration Project of PrEP and ART. Presented at: Conference on Retroviruses and Opportunistic Infections; February 23-26, 2015; Seattle, WA.
150. Kaiser R, Bunnell R, Hightower A, et al. Factors associated with HIV infection in married or cohabitating couples in Kenya: results from a nationally representative study. PLoS One. 2011; 6 (3): e17842.
151. Weller S, Davis K,. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev. 2002;(1): CD003255.
152. Volk JE, Marcus JL, Phengrasamy T, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting [published online September 1, 2015]. Clin Infect Dis. 2015. pii: civ778.
153. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A,. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005; 2 (11): e298.
154. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007; 369 (9562): 643-656.
155. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007; 369 (9562): 657-666.
156. Smith DK, Grohskopf LA, Black RJ, et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep. 2005; 54 (RR-2): 1-20.
157. Wiessing L, Likataviius G, Klempová D, Hedrich D, Nardone A, Griffiths P,. Associations between availability and coverage of HIV-prevention measures and subsequent incidence of diagnosed HIV infection among injection drug users. Am J Public Health. 2009; 99 (6): 1049-1052.
158. Bruce RD, Dvoryak S, Sylla L, Altice FL,. HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine-programme description and policy implications. Int J Drug Policy. 2007; 18 (4): 326-328.
159. World Health Organization. Guidelines on Post-Exposure Prophylaxis for HIV and the Use of Co-Trimoxazole Prophylaxis for HIV-Related Infections Among Adults, Adolescents and Children: Recommendations for a Public Health Approach. Geneva, Switzerland: World Health Organization; 2014. Web site. http://www.who.int/hiv/pub/guidelines/arv2013/december2014supplementARV.pdf. Accessed October 15, 2015.
160. World Health Organization. Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care for Key Populations. Geneva, Switzerland: World Health Organization; 2014. Web site. http://apps.who.int/iris/bitstream/10665/128048/1/9789241507431-eng.pdf?ua=1&ua=1. Accessed October 15, 2015.
161. Thurman TR, Haas LJ, Dushimimana A, Lavin B, Mock N,. Evaluation of a case management program for HIV clients in Rwanda. AIDS Care. 2010; 22 (6): 759-765.
162. Kushel MB, Colfax G, Ragland K, Heineman A, Palacio H, Bangsberg DR,. Case management is associated with improved antiretroviral adherence and CD4+ cell counts in homeless and marginally housed individuals with HIV infection. Clin Infect Dis. 2006; 43 (2): 234-242.
163. Craw JA, Gardner LI, Marks G, et al. Brief strengths-based case management promotes entry into HIV medical care: results of the antiretroviral treatment access study-II. J Acquir Immune Defic Syndr. 2008; 47 (5): 597-606.
164. Konate I, Traore L, Ouedraogo A, et al. Linking HIV prevention and care for community interventions among high-risk women in Burkina Faso-the ARNS 1222 "Yerelon" cohort. J Acquir Immune Defic Syndr. 2011; 57 (suppl 1): S50-S54.
165. Hightow-Weidman LB, Jones K, Wohl AR, et al. Early linkage and retention in care: findings from the outreach, linkage, and retention in care initiative among young men of color who have sex with men. AIDS Patient Care STDs. 2011; 25 (suppl 1): S31-S38.
166. Mugavero MJ, Norton WE, Saag MS,. Health care system and policy factors influencing engagement in HIV medical care: piecing together the fragments of a fractured health care delivery system. Clin Infect Dis. 2011; 52 (suppl 2): S238-S246.
167. Grinsztejn B, Hosseinipour MC, Ribaudo HJ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014; 14 (4): 281-290.
168. Cohen M, Chen Y, McCauley M,. Antiretroviral Treatment Prevents HIV Transmission: Final Results from the HPTN 052 Randomized Controlled Trial. Presented at: 8th IAS Conference on HIV Pathogenesis Treatment and Prevention; July 18-22, 2015; Vancouver, Canada.
169. Roger A, Cambiano V, Brunn T, et al. HIV Transmission Risk through Condomless Sex if HIV+ Partner on Suppressive ART: PARTNER Study. Presented at: Conference on Retroviruses and Opportunistic Infections; March 3-6, 2014; Boston, MA.
170. TEMPRANO ANRS. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015; 373 (9): 808-822.
171. Centers for Disease Control and Prevention, National Institutes of Health, HIV Medical Association. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents.; 2015. Web site. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult-oi.pdf. Accessed October 15, 2015.
172. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010; 362 (8): 697-706.
173. World Health Organization. March 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2014. Web site. http://www.who.int/hiv/pub/guidelines/arv2013/arvs2013upplement-march2014/en/. Accessed October 15, 2015.
174. Gale HB, Gitterman SR, Hoffman HJ, et al. Is frequent CD4+ T-lymphocyte count monitoring necessary for persons with counts >=300 cells/muL and HIV-1 suppression? Clin Infect Dis. 2013; 56 (9): 1340-1343.
175. Hyle EP, Sax PE, Walensky RP,. Potential savings by reduced CD4 monitoring in stable patients with HIV receiving antiretroviral therapy. JAMA Intern Med. 2013; 173 (18): 1746-1748.
176. Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014; 383 (9936): 2222-2231.
177. Rockstroh JK, DeJesus E, Lennox JL, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr. 2013; 63 (1): 77-85.
178. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012; 379 (9835): 2439-2448.
179. Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013; 369 (19): 1807-1818.
180. Arribas JR, Pialoux G, Gathe J, et al. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. Lancet Infect Dis. 2014; 14 (7): 581-589.
181. Pozniak A, Markowitz M, Mills A, et al. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial. Lancet Infect Dis. 2014; 14 (7): 590-599.
182. Nachega JB, Parienti JJ, Uthman OA, et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. Clin Infect Dis. 2014; 58 (9): 1297-1307.
183. U.S Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Bethesda, MD: U.S Department of Health and Human Services; 2014. Web site. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed October 15, 2015.
184. Young B, Hart RL, Buchacz K, Scott M, Palella F, Brooks JT,. HIV viral load monitoring frequency and risk of treatment failure among immunologically stable HIV-infected patients prescribed combination antiretroviral therapy [published online August 20, 2015]. J Int Assoc Provid AIDS Care. 2015.
185. Baxter JD, Dunn D, White E, et al. Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015; 16 (suppl 1): 77-87.
186. Rhee SY, Blanco JL, Jordan MR, et al. Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis. PLoS Med. 2015; 12 (4): e1001810.
187. Kuritzkes DR, Lalama CM, Ribaudo HJ, et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis. 2008; 197 (6): 867-870.
188. Wheeler WH, Ziebell RA, Zabina H, et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS. 2010; 24 (8): 1203-1212.
189. Ross L, Lim ML, Liao Q, et al. Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naive HIV-infected individuals from 40 United States cities. HIV Clin Trials. 2007; 8 (1): 1-8.
190. Vray M, Meynard JL, Dalban C, et al. Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088). Antivir Ther. 2003; 8 (5): 427-434.
191. Wegner SA, Wallace MR, Aronson NE, et al. Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial. Clin Infect Dis. 2004; 38 (5): 723-730.
192. Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS. 2002; 16 (2): 209-218.
193. Palella FJ Jr, Armon C, Buchacz K, et al. The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: a cohort study. Ann Intern Med. 2009; 151 (2): 73-84.
194. Hong SY, Jonas A, DeKlerk M, et al. Population-based surveillance of HIV drug resistance emerging on treatment and associated factors at sentinel antiretroviral therapy sites in Namibia. J Acquir Immune Defic Syndr. 2015; 68 (4): 463-471.
195. Kredo T, Ford N, Adeniyi FB, Garner P,. Decentralising HIV treatment in lower- and middle-income countries. Cochrane Database Syst Rev. 2013; 6: CD009987.
196. Chu C, Umanski G, Blank A, Grossberg R, Selwyn PA,. HIV-infected patients and treatment outcomes: an equivalence study of community-located, primary care-based HIV treatment vs. hospital-based specialty care in the Bronx, New York. AIDS Care. 2010; 22 (12): 1522-1529.
197. Bucher JB, Thomas KM, Guzman D, Riley E, Dela Cruz N, Bangsberg DR,. Community-based rapid HIV testing in homeless and marginally housed adults in San Francisco. HIV Med. 2007; 8 (1): 28-31.
198. World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva, Switzerland: World Health Organization; 2013. Web site. http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727-eng.pdf. Accessed October 15, 2015.
199. Myers JJ, Modica C, Dufour MS, Bernstein C, McNamara K,. Routine rapid HIV screening in six community health centers serving populations at risk. J Gen Intern Med. 2009; 24 (12): 1269-1274.
200. Decroo T, Koole O, Remartinez D, et al. Four-year retention and risk factors for attrition among members of community ART groups in Tete, Mozambique. Trop Med Int Health. 2014; 19 (5): 514-521.
201. Murphy P, Cocohoba J, Tang A, Pietrandoni G, Hou J, Guglielmo BJ,. Impact of HIV-specialized pharmacies on adherence and persistence with antiretroviral therapy. AIDS Patient Care STDs. 2012; 26 (9): 526-531.
202. Henderson KC, Hindman J, Johnson SC, Valuck RJ, Kiser JJ,. Assessing the effectiveness of pharmacy-based adherence interventions on antiretroviral adherence in persons with HIV. AIDS Patient Care STDs. 2011; 25 (4): 221-228.
203. Hirsch JD, Rosenquist A, Best BM, Miller TA, Gilmer TP,. Evaluation of the first year of a pilot program in community pharmacy: HIV/AIDS medication therapy management for Medi-Cal beneficiaries. J Manag Care Pharm. 2009; 15 (1): 32-41.
204. Grimsrud A, Patten G, Sharp J, Myer L, Wilkinson L, Bekker LG,. Extending dispensing intervals for stable patients on ART. J Acquir Immune Defic Syndr. 2014; 66 (2): e58-e60.
205. Lucas GM, Chaisson RE, Moore RD,. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999; 131 (2): 81-87.
206. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000; 133 (1): 21-30.
207. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis. 2001; 33 (8): 1417-1423.
208. Bangsberg DR, Charlebois ED, Grant RM, et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS. 2003; 17 (13): 1925-1932.
209. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE,. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis. 2003; 37 (8): 1112-1118.
210. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis. 2005; 191 (3): 339-347.
211. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001; 15 (9): 1181-1183.
212. Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS. 2002; 16 (7): 1051-1058.
213. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006; 43 (1): 78-84.
214. Wood E, Hogg RS, Yip B, Moore D, Harrigan PR, Montaner JS,. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts ≥200 cells/microl. AIDS. 2006; 20 (8): 1117-1123.
215. Bacheler LT, Anton ED, Kudish P, et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother. 2000; 44 (9): 2475-2484.
216. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA. 2006; 296 (6): 679-690.
217. Hu YW, Kinsler JJ, Sheng Z, Kang T, Bingham T, Frye DM,. Using laboratory surveillance data to estimate engagement in care among persons living with HIV in Los Angeles County, 2009. AIDS Patient Care STDs. 2012; 26 (8): 471-478.
218. Naar-King S, Bradford J, Coleman S, Green-Jones M, Cabral H, Tobias C,. Retention in care of persons newly diagnosed with HIV: outcomes of the Outreach Initiative. AIDS Patient Care STDs. 2007; 21 (suppl 1): S40-S48.
219. Mugavero MJ, Davila JA, Nevin CR, Giordano TP,. From access to engagement: measuring retention in outpatient HIV clinical care. AIDS Patient Care STDs. 2010; 24 (10): 607-613.
220. Yehia BR, Fleishman JA, Metlay JP, et al. Comparing different measures of retention in outpatient HIV care. AIDS. 2012; 26 (9): 1131-1139.
221. Mugavero MJ, Westfall AO, Zinski A, et al. Measuring retention in HIV care: the elusive gold standard. J Acquir Immune Defic Syndr. 2012; 61 (5): 574-580.
222. Herwehe J, Wilbright W, Abrams A, et al. Implementation of an innovative, integrated electronic medical record (EMR) and public health information exchange for HIV/AIDS. J Am Med Inform Assoc. 2012; 19 (3): 448-452.
223. Nglazi MD, Kaplan R, Wood R, Bekker L-G, Lawn SD,. Identification of losses to follow-up in a community-based antiretroviral therapy clinic in South Africa using a computerized pharmacy tracking system. BMC Infect Dis. 2010; 10: 329.
224. El-Khatib Z, Ekstrom AM, Coovadia A, et al. Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa-a prospective cohort study. BMC Public Health. 2011; 11: 88.
225. Palombi L, Marazzi MC, Guidotti G, et al. Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral-treated patients in sub-Saharan African sites with comprehensive monitoring availability. Clin Infect Dis. 2009; 48 (1): 115-122.
226. Ahonkhai AA, Noubary F, Munro A, et al. Not all are lost: interrupted laboratory monitoring, early death, and loss to follow-up (LTFU) in a large South African treatment program. PLoS One. 2012; 7 (3): e32993.
227. Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA,. Self-Report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav. 2006; 10 (3): 227-245.
228. Walshe L, Saple DG, Mehta SH, Shah B, Bollinger RC, Gupta A,. Physician estimate of antiretroviral adherence in India: poor correlation with patient self-report and viral load. AIDS Patient Care STDs. 2010; 24 (3): 189-195.
229. Murri R, Ammassari A, Trotta MP, et al. Patient-reported and physician-estimated adherence to HAART: social and clinic center-related factors are associated with discordance. J Gen Intern Med. 2004; 19 (11): 1104-1110.
230. Miller LG, Liu H, Hays RD, et al. How well do clinicians estimate patients' adherence to combination antiretroviral therapy? J Gen Intern Med. 2002; 17 (1): 1-11.
231. McMahon JH, Jordan MR, Kelley K, et al. Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. Clin Infect Dis. 2011; 52 (4): 493-506.
232. Saberi P, Johnson MO,. Technology-based self-care methods of improving antiretroviral adherence: a systematic review. PLoS One. 2011; 6 (11): e27533.
233. Lester RT, Ritvo P, Mills EJ, et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet. 2010; 376 (9755): 1838-1845.
234. Pop-Eleches C, Thirumurthy H, Habyarimana JP, et al. Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. AIDS. 2011; 25 (6): 825-834.
235. Horvath T, Azman H, Kennedy GE, Rutherford GW,. Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection. Cochrane Database Syst Rev. 2012; 3: CD009756.
236. Finitsis DJ, Pellowski JA, Johnson BT,. Text message intervention designs to promote adherence to antiretroviral therapy (ART): a meta-analysis of randomized controlled trials. PLoS One. 2014; 9 (2): e88166.
237. Chung MH, Richardson BA, Tapia K, et al. A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes. PLoS Med. 2011; 8 (3): e1000422.
238. Andrade AS, McGruder HF, Wu AW, et al. A programmable prompting device improves adherence to highly active antiretroviral therapy in HIV-infected subjects with memory impairment. Clin Infect Dis. 2005; 41 (6): 875-882.
239. Hardy H, Kumar V, Doros G, et al. Randomized controlled trial of a personalized cellular phone reminder system to enhance adherence to antiretroviral therapy. AIDS Patient Care STDs. 2011; 25 (3): 153-161.
240. Henry SR, Goetz MB, Asch SM,. The effect of automated telephone appointment reminders on HIV primary care no-shows by veterans. J Assoc Nurses AIDS Care. 2012; 23 (5): 409-418.
241. Maduka O, Tobin-West CI,. Adherence counseling and reminder text messages improve uptake of antiretroviral therapy in a tertiary hospital in Nigeria. Niger J Clin Pract. 2013; 16 (3): 302-308.
242. Tuldra A, Fumaz CR, Ferrer MJ, et al. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2000; 25 (3): 221-228.
243. Javanbakht M, Prosser P, Grimes T, Weinstein M, Farthing C,. Efficacy of an individualized adherence support program with contingent reinforcement among nonadherent HIV-positive patients: results from a randomized trial. J Int Assoc Physicians AIDS Care (Chic). 2006; 5 (4): 143-150.
244. Amico KR, Harman JJ, Johnson BT,. Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996 to 2004. J Acquir Immune Defic Syndr. 2006; 41 (3): 285-297.
245. de Bruin M, Viechtbauer W, Schaalma HP, Kok G, Abraham C, Hospers HJ,. Standard care impact on effects of highly active antiretroviral therapy adherence interventions: a meta-analysis of randomized controlled trials. Arch Intern Med. 2010; 170 (3): 240-250.
246. Higa DH, Marks G, Crepaz N, Liau A, Lyles CM,. Interventions to improve retention in HIV primary care: a systematic review of U.S. studies. Curr HIV/AIDS Rep. 2012; 9 (4): 313-325.
247. Gardner LI, Marks G, Craw JA, et al. A low-effort, clinic-wide intervention improves attendance for HIV primary care. Clin Infect Dis. 2012; 55 (8): 1124-1134.
248. Petersen ML, Wang Y, van der Laan MJ, Guzman D, Riley E, Bangsberg DR,. Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: a marginal structural model analysis. Clin Infect Dis. 2007; 45 (7): 908-915.
249. Ford N, Nachega JB, Engel ME, Mills EJ,. Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials. Lancet. 2009; 374 (9707): 2064-2071.
250. Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH,. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. Clin Infect Dis. 2007; 45 (6): 770-778.
251. Mitty JA, Macalino GE, Bazerman LB, et al. The use of community-based modified directly observed therapy for the treatment of HIV-infected persons. J Acquir Immune Defic Syndr. 2005; 39 (5): 545-550.
252. Berg KM, Litwin A, Li X, Heo M, Arnsten JH,. Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: a randomized controlled trial. Drug Alcohol Depend. 2011; 113 (2-3): 192-199.
253. Tehrani ASS, Springer SA, Qiu J, Herme M, Wickersham J, Altice FL,. Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community-a potential conduit to improved HIV treatment outcomes. Contemporary Clinical Trials. 2012; 33 (2): 436-444.
254. Lucas GM, Mullen BA, Weidle PJ, Hader S, McCaul ME, Moore RD,. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clin Infect Dis. 2006; 42 (11): 1628-1635.
255. Maru DS, Bruce RD, Walton M, Springer SA, Altice FL,. Persistence of virological benefits following directly administered antiretroviral therapy among drug users: results from a randomized controlled trial. J Acquir Immune Defic Syndr. 2009; 50 (2): 176-181.
256. Lucas GM, Chaudhry A, Hsu J, et al. Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: a randomized trial. Ann Intern Med. 2010; 152 (11): 704-711.
257. Tran BX, Ohinmaa A, Duong AT, et al. Cost-effectiveness of integrating methadone maintenance and antiretroviral treatment for HIV-positive drug users in Vietnam's injection-driven HIV epidemics. Drug Alcohol Depend. 2012; 125 (3): 260-266.
258. Marks G, Gardner LI, Craw J, Crepaz N,. Entry and retention in medical care among HIV-diagnosed persons: a meta-analysis. AIDS. 2010; 24 (17): 2665-2678.
259. Bradley H, Hall HI, Wolitski RJ, et al. Vital Signs: HIV diagnosis, care, and treatment among persons living with HIV-United States, 2011. MMWR Morb Mortal Wkly Rep. 2014; 63 (47): 1113-1117.
260. Alvarez-Uria G, Pakam R, Midde M, Naik PK,. Entry, retention, and virological suppression in an HIV cohort study in India: description of the cascade of care and implications for reducing HIV-related mortality in low- and middle-income countries. Interdiscip Perspect Infect Dis. 2013; 2013: 384805.
261. Ashman JJ, Conviser R, Pounds MB,. Associations between HIV-positive individuals' receipt of ancillary services and medical care receipt and retention. AIDS Care. 2002; 14 (suppl 1): S109-S118.
262. Sherer R, Stieglitz K, Narra J, et al. HIV multidisciplinary teams work: support services improve access to and retention in HIV primary care. AIDS Care. 2002; 14 (suppl 1): S31-S44.
263. Gardner LI, Giordano TP, Marks G, et al. Enhanced personal contact with HIV patients improves retention in primary care: a randomized trial in 6 US HIV clinics. Clin Infect Dis. 2014; 59 (5): 725-734.
264. Shrestha RK, Gardner L, Marks G, et al. Estimating the cost of increasing retention in care for HIV-infected patients: results of the CDC/HRSA retention in care trial. J Acquir Immune Defic Syndr. 2015; 68 (3): 345-350.
265. Udeagu CC, Webster TR, Bocour A, Michel P, Shepard CW,. Lost or just not following up: public health effort to re-engage HIV-infected persons lost to follow-up into HIV medical care. AIDS. 2013; 27 (14): 2271-2279.
266. World Health Organization. HIV and Adolescents: Guidance for HIV testing and Counseling and Care for Adolescents Living with HIV: Recommendations for a Public Health Approach and Considerations for Policy Makers and Managers. Geneva, Switzerland: World Health Organization; 2013. Web site. http://apps.who.int/iris/bitstream/10665/94334/1/9789241506168-eng.pdf. Accessed October 15, 2015.
267. Ramirez-Avila L, Nixon K, Noubary F, et al. Routine HIV testing in adolescents and young adults presenting to an outpatient clinic in Durban, South Africa. PLoS One. 2012; 7 (9): e45507.
268. Jaspan HB, Li R, Johnson L, Bekker L-G,. The emerging need for adolescent-focused HIV care in South Africa. Southern Afr J HIV Med. 2009; 10 (4): 9-11.
269. Mathews C, Guttmacher SJ, Flisher AJ, et al. The quality of HIV testing services for adolescents in Cape Town, South Africa: do adolescent-friendly services make a difference? J Adolesc Health. 2009; 44 (2): 188-190.
270. Bikaako-Kajura W, Luyirika E, Purcell DW, et al. Disclosure of HIV status and adherence to daily drug regimens among HIV-infected children in Uganda. AIDS Behav. 2006; 10 (4 suppl): S85-S93.
271. Vreeman RC, Nyandiko WM, Ayaya SO, Walumbe EG, Marrero DG, Inui TS,. The perceived impact of disclosure of pediatric HIV status on pediatric antiretroviral therapy adherence, child well-being, and social relationships in a resource-limited setting. AIDS Patient Care STDs. 2010; 24 (10): 639-649.
272. Spiegel HM,. Nondisclosure of HIV status in adolescence. Adolesc Med State Art Rev. 2011; 22 (2): 277-282.
273. Smith R, Rossetto K, Peterson BL,. A meta-analysis of disclosure of one's HIV-positive status, stigma and social support. AIDS Care. 2008; 20 (10): 1266-1275.
274. Medin G, Garcia-Navarro C, Navarro Gomez M, et al. Disease disclosure, treatment adherence, and behavioural profile in a cohort of vertically acquired HIV-infected adolescents. NeuroCoRISpeS study. AIDS Care. 2015: 1-7.
275. Pai ALH, Ostendorf HM,. Treatment adherence in adolescents and young adults affected by chronic illness during the health care transition from pediatric to adult health care: a literature review. Child Health Care. 2011; 40 (1): 16-33.
276. Fair CD, Sullivan K, Gatto A,. Indicators of transition success for youth living with HIV: perspectives of pediatric and adult infectious disease care providers. AIDS Care. 2011; 23 (8): 965-970.
277. Gardner EM, Maravi ME, Rietmeijer C, Davidson AJ, Burman WJ,. The association of adherence to antiretroviral therapy with healthcare utilization and costs for medical care. Appl Health Econ Health Policy. 2008; 6 (2-3): 145-155.
278. Dombrowski JC, Kent JB, Buskin SE, Stekler JD, Golden MR,. Population-based metrics for the timing of HIV diagnosis, engagement in HIV care, and virologic suppression. AIDS. 2012; 26 (1): 77-86.
279. Nosyk B, Montaner JS, Colley G, et al. The cascade of HIV care in British Columbia, Canada, 1996-2011: a population-based retrospective cohort study. Lancet Infect Dis. 2014; 14 (1): 40-49.
280. Institute of Medicine. Monitoring HIV Care in the United States: A Strategy for Generating National Estimates of HIV Care and Coverage. Washington, DC: Institute of Medicine; 5, 2012. Web site. http://iom.edu/Reports/2012/Monitoring-HIV-Care-in-the-United-States-A-Strategy-for-Generating-National-Estimates-of-HIV-Care-and-Coverage.aspx. Accessed October 15, 2015.
281. World Health Organization. Metrics for monitoring the cascade of HIV testing, care and treatment services in Asia and the Pacific. Geneva: World Health Organization; 2014. Web site. http://www.searo.who.int/entity/hiv/hiv-metrics.pdf. Accessed October 15, 2015.
282. National AIDS Manual. The treatment cascade.; 2014. Web site. http://www.aidsmap.com/The-treatment-cascade/page/2835702/. Accessed October 15, 2015.
283. Raymond A, Hill A, Pozniak A,. Large disparities in HIV treatment cascades between eight European and high-income countries-analysis of break points. J Int AIDS Soc. 2014; 17 (4 suppl 3): 19507.
284. Joint United Nations Programme on HIV/AIDS (UNAIDS). Spectrum/EPP 2014.; 2014. Web site. http://www.unaids.org/en/dataanalysis/datatools/spectrumepp2013. Accessed October 15, 2015.
285. McNairy ML, Lamb MR, Abrams EJ, et al. Use of a comprehensive HIV care cascade for evaluating HIV program performance: findings from 4 sub-Saharan African countries. J Acquir Immune Defic Syndr. 2015; 70 (2): e44-e51.
286. Lowrance DW, Makombe S, Harries AD, et al. A public health approach to rapid scale-up of antiretroviral treatment in Malawi during 2004-2006. J Acquir Immune Defic Syndr. 2008; 49 (3): 287-293.
287. Nsanzimana S, Remera E, Kanters S, et al. Life expectancy among HIV-positive patients in Rwanda: a retrospective observational cohort study. Lancet Glob Health. 2015; 3 (3): e169-e177.
288. Kohler P, Schmidt AJ, Cavassini M, et al. The HIV care cascade in Switzerland: reaching the UNAIDS/WHO targets for patients diagnosed with HIV. AIDS. 2015; Epub.
289. Strathdee SA, Hallett TB, Bobrova N, et al. HIV and risk environment for injecting drug users: the past, present, and future. Lancet. 2010; 376 (9737): 268-284.
290. Shannon K, Strathdee SA, Goldenberg SM, et al. Global epidemiology of HIV among female sex workers: influence of structural determinants. Lancet. 2014; 385 (9962): 55-71.
291. Weiser SD, Yuan C, Guzman D, et al. Food insecurity and HIV clinical outcomes in a longitudinal study of urban homeless and marginally housed HIV-infected individuals. AIDS. 2013; 27 (18): 2953-2958.
292. Tyler K, Melander L,. The effect of drug and sexual risk behaviours with social network and non-network members on homeless youths' sexually transmissible infections and HIV testing. Sex Health. 2010; 7 (4): 434-440.
293. Milloy MJ, Montaner JS, Wood E,. Incarceration of people living with HIV/AIDS: implications for treatment-as-prevention. Curr HIV/AIDS Rep. 2014; 11 (3): 308-316.
294. Mimiaga MJ, O'Cleirigh C, Biello KB, et al. The effect of psychosocial syndemic production on 4-year HIV incidence and risk behavior in a large cohort of sexually active men who have sex with men. J Acquir Immune Defic Syndr. 2015; 68 (3): 329-336.
295. Michalopoulos LM, Aifah A, El-Bassel N,. A systematic review of HIV risk behaviors and trauma among forced and unforced migrant populations from low and middle-income countries: state of the literature and future directions. AIDS Behav. 2015. Web site. http://link.springer.com/article/10.1007/s10461-015-1014-1. Accessed October 15, 2015.
296. Des Jarlais DC, McCarty D, Vega WA, Bramson H,. HIV infection among people who inject drugs: the challenge of racial/ethnic disparities. Am Psychol. 2013; 68 (4): 274-285.
297. Earnshaw VA, Bogart LM, Dovidio JF, Williams DR,. Stigma and racial/ethnic HIV disparities: moving toward resilience. Am Psychol. 2013; 68 (4): 225-236.
298. Des Jarlais DC, Bramson HA, Wong C, et al. Racial/ethnic disparities in HIV infection among people who inject drugs: an international systematic review and meta-analysis. Addiction. 2012; 107 (12): 2087-2095.
299. Chan KY, Stoove MA, Sringernyuang L, Reidpath DD,. Stigmatization of AIDS patients: disentangling Thai nursing students' attitudes towards HIV/AIDS, drug use, and commercial sex. AIDS Behav. 2008; 12 (1): 146-157.
300. Genberg BL, Hlavka Z, Konda KA, et al. A comparison of HIV/AIDS-related stigma in four countries: negative attitudes and perceived acts of discrimination towards people living with HIV/AIDS. Soc Sci Med. 2009; 68 (12): 2279-2287.
301. Shannon K, Csete J,. Violence, condom negotiation, and HIV/STI risk among sex workers. JAMA. 2010; 304 (5): 573-574.
302. Kouyoumdjian FG, Findlay N, Schwandt M, Calzavara LM,. A systematic review of the relationships between intimate partner violence and HIV/AIDS. PLoS One. 2013; 8 (11): e81044.
303. Eaton LA, Driffin DD, Kegler C, et al. The role of stigma and medical mistrust in the routine health care engagement of black men who have sex with men. Am J Public Health. 2015; 105 (2): e75-e82.
304. Palepu A, Milloy MJ, Kerr T, Zhang R, Wood E,. Homelessness and adherence to antiretroviral therapy among a cohort of HIV-infected injection drug users. J Urban Health. 2011; 88 (3): 545-555.
305. Dickson-Gomez J, Owczarzak J, St Lawrence J, et al. Beyond the ball: implications for HIV risk and prevention among the constructed families of African American men who have sex with men. AIDS Behav. 2014; 18 (11): 2156-2168.
306. Nelson P, Mathers B, Cowie B, et al. The epidemiology of viral hepatitis among people who inject drugs: results of global systematic reviews. Lancet. 2011; 378 (9791): 571-583.
307. Jittimanee SX, Nateniyom S, Kittikraisak W, et al. Social stigma and knowledge of tuberculosis and HIV among patients with both diseases in Thailand. PLoS One. 2009; 4 (7): e6360.
308. Kerr T, Fairbairn N, Hayashi K, et al. Difficulty accessing syringes and syringe borrowing among injection drug users in Bangkok, Thailand. Drug Alcohol Rev. 2010; 29 (2): 157-161.
309. Garfein RS, Golub ET, Greenberg AE, et al. A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. AIDS. 2007; 21 (14): 1923-1932.
310. Hayashi K, Wood E, Wiebe L, Qi J, Kerr T,. An external evaluation of a peer-run outreach-based syringe exchange in Vancouver, Canada. Int J Drug Policy. 2010; 21 (5): 418-421.
311. Broadhead RS, Heckathorn DD, Weakliem DL, et al. Harnessing peer networks as an instrument for AIDS prevention: results from a peer-driven intervention. Public Health Rep. 1998; 113 (suppl 1): 42-57.
312. Robertson AM, Rangel MG, Lozada R, Vera A, Ojeda VD,. Male injection drug users try new drugs following U.S. deportation to Tijuana, Mexico. Drug Alcohol Depend. 2012; 120 (1-3): 142-148.
313. Wolfe D, Carrieri MP, Shepard D,. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet. 2010; 376 (9738): 355-366.
314. Wood E, Werb D, Kazatchkine M, et al. Vienna Declaration: a call for evidence-based drug policies. Lancet. 2010; 376 (9738): 310-312.